{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:49:14Z","timestamp":1771505354075,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2022,6,11]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Respiratory infections are ubiquitous. The COVID-19 pandemic has refocused our attention on how morbid and potentially fatal they can be, and how host factors have an impact on the clinical course and outcomes. Due to a range of vulnerabilities, patients with sarcoidosis may be at higher risk of poor outcomes from respiratory infections. The objective of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study is to determine the short-term and long-term impacts of respiratory viral illnesses (COVID-19 and non-COVID-19) in sarcoidosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>Up to 20 clinical sites across the USA are participating in the recruitment of 2000 patients for this observational, prospective study. To ensure that the study cohort is representative of the general population with sarcoidosis, participating sites include those dedicated to reaching under-represented minorities or patients from non-urban areas. Baseline data on demographic features, comorbidities, sarcoidosis characteristics and pre-enrolment lung function will be captured at study entry. During this 3-year study, all acute respiratory infectious events (from SARS-CoV-2 and any other respiratory pathogen) will be assessed and recorded at quarterly intervals. The level of required medical care and survival outcomes determine infection severity, and the impact of infection on quality of life measures will be recorded. Post-infection lung function and imaging results will measure the long-term impact on the trajectory of sarcoidosis. Patients will be analysed according to the clinical phenotypes of cardiac and fibrotic pulmonary sarcoidosis. Control groups include non-infected patients with sarcoidosis and patients with non-sarcoidosis interstitial lung disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Each site received local institutional review board approval prior to enrolling patients, with the consent process determined by local institution standards. Data will be published in a timely manner (goal &lt;12 months) at the conclusion of the 3-year follow-up period and will be made available upon request.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001254","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T12:52:16Z","timestamp":1658839936000},"page":"e001254","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-2894","authenticated-orcid":false,"given":"Rachel","family":"Strykowski","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Pulmonary and Critical Care, University of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya C","family":"Patel","sequence":"additional","affiliation":[{"name":"Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manny Ribeiro","family":"Neto","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine, Respiratory Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry M","family":"Hena","sequence":"additional","affiliation":[{"name":"Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, New York University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mridu","family":"Gulati","sequence":"additional","affiliation":[{"name":"Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIsa A","family":"Maier","sequence":"additional","affiliation":[{"name":"Divisions of Cardiology and Pulmonary Medicine, National Jewish Health, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Patterson","sequence":"additional","affiliation":[{"name":"Medicine, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Medicine, Brighton and Sussex Medical School, Brighton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2025083110455102000_9.1.e001254.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0251ST"},{"key":"2025083110455102000_9.1.e001254.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071714"},{"key":"2025083110455102000_9.1.e001254.3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.chest.2017.11.030","article-title":"The pathogenesis of pulmonary sarcoidosis and implications for treatment","volume":"153","author":"Patterson","year":"2018","journal-title":"Chest"},{"key":"2025083110455102000_9.1.e001254.4","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-121"},{"key":"2025083110455102000_9.1.e001254.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a multidisciplinary approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front Immunol"},{"key":"2025083110455102000_9.1.e001254.6","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2025083110455102000_9.1.e001254.7","doi-asserted-by":"crossref","first-page":"729229","DOI":"10.3389\/fmed.2021.729229","article-title":"Stable extent of recurrently active cardiac and cutaneous sarcoidosis","volume":"8","author":"Patterson","year":"2021","journal-title":"Front Med"},{"key":"2025083110455102000_9.1.e001254.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00138913"},{"key":"2025083110455102000_9.1.e001254.9","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201303-069FR"},{"key":"2025083110455102000_9.1.e001254.10","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1183\/09031936.01.18s320002","article-title":"Interstitial lung diseases: an epidemiological overview","volume":"32","author":"Demedts","year":"2001","journal-title":"Eur Respir J Suppl"},{"key":"2025083110455102000_9.1.e001254.11","unstructured":"Valeyre D , Fressynet O , Dion G , et al . . Epid\u00e9miologie."},{"key":"2025083110455102000_9.1.e001254.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02419-2016"},{"key":"2025083110455102000_9.1.e001254.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters","volume":"11","author":"Hena","year":"2020","journal-title":"Front Immunol"},{"key":"2025083110455102000_9.1.e001254.14","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009096"},{"key":"2025083110455102000_9.1.e001254.15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1055\/s-0040-1710080","article-title":"Health-Related quality of life in sarcoidosis","volume":"41","author":"Obi","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2025083110455102000_9.1.e001254.16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1513\/AnnalsATS.202006-607OC","article-title":"Evaluating the minimal clinically important difference of the King's sarcoidosis questionnaire in a multicenter prospective study","volume":"18","author":"Baughman","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110455102000_9.1.e001254.17","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00141-2018"},{"key":"2025083110455102000_9.1.e001254.18","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.09.016","article-title":"Work ability before and after sarcoidosis diagnosis in Sweden","volume":"144S","author":"Arkema","year":"2018","journal-title":"Respir Med"},{"key":"2025083110455102000_9.1.e001254.19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/13696998.2017.1351371","article-title":"Economic burden of sarcoidosis in a commercially-insured population in the United States","volume":"20","author":"Rice","year":"2017","journal-title":"J Med Econ"},{"key":"2025083110455102000_9.1.e001254.20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01816-2"},{"key":"2025083110455102000_9.1.e001254.21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S2213-2600(21)00095-3","article-title":"Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study","volume":"9","author":"Aveyard","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025083110455102000_9.1.e001254.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04474-2020"},{"key":"2025083110455102000_9.1.e001254.23","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1164\/rccm.202007-2794OC","article-title":"Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study","volume":"202","author":"Drake","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110455102000_9.1.e001254.24","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1164\/rccm.202006-2441LE","article-title":"Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study","volume":"202","author":"Esposito","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110455102000_9.1.e001254.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106538"},{"key":"2025083110455102000_9.1.e001254.26","doi-asserted-by":"crossref","first-page":"588527","DOI":"10.3389\/fmed.2020.588527","article-title":"Case series: COVID-19 in African American patients with sarcoidosis","volume":"7","author":"Manansala","year":"2020","journal-title":"Front Med"},{"key":"2025083110455102000_9.1.e001254.27","doi-asserted-by":"crossref","first-page":"689539","DOI":"10.3389\/fmed.2021.689539","article-title":"Treatment of COVID-19 in patients with sarcoidosis","volume":"8","author":"Kondle","year":"2021","journal-title":"Front Med"},{"key":"2025083110455102000_9.1.e001254.28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00408-020-00392-9","article-title":"Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS\u2011CoV\u20112","volume":"198","author":"Morgenthau","year":"2020","journal-title":"Lung"},{"key":"2025083110455102000_9.1.e001254.29","doi-asserted-by":"crossref","DOI":"10.3390\/v13061000","article-title":"Characterization and outcomes of SARS-CoV-2 infection in patients with sarcoidosis","volume":"13","author":"Brito-Zer\u00f3n","year":"2021","journal-title":"Viruses"},{"key":"2025083110455102000_9.1.e001254.30","article-title":"Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025083110455102000_9.1.e001254.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046837"},{"key":"2025083110455102000_9.1.e001254.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.4.499"},{"key":"2025083110455102000_9.1.e001254.33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ccm.2016.11.014","article-title":"Respiratory viral infections in chronic lung diseases","volume":"38","author":"Britto","year":"2017","journal-title":"Clin Chest Med"},{"key":"2025083110455102000_9.1.e001254.34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.chest.2017.03.033","article-title":"The role of infection in interstitial lung diseases: a review","volume":"152","author":"Azadeh","year":"2017","journal-title":"Chest"},{"key":"2025083110455102000_9.1.e001254.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201010-1752OC"},{"key":"2025083110455102000_9.1.e001254.36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.chest.2021.08.010","article-title":"Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing","volume":"161","author":"Singh","year":"2022","journal-title":"Chest"},{"key":"2025083110455102000_9.1.e001254.37","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: wells law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025083110455102000_9.1.e001254.38","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00281-2019","article-title":"King's brief interstitial lung disease questionnaire: responsiveness and minimum clinically important difference","volume":"54","author":"Nolan","year":"2019","journal-title":"Eur Respir J"},{"key":"2025083110455102000_9.1.e001254.39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00408-017-0012-7","article-title":"Hospitalization among patients with sarcoidosis: a population-based cohort study 1987-2015","volume":"195","author":"Ungprasert","year":"2017","journal-title":"Lung"},{"key":"2025083110455102000_9.1.e001254.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025083110455102000_9.1.e001254.41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020"},{"key":"2025083110455102000_9.1.e001254.42","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00105805"},{"key":"2025083110455102000_9.1.e001254.43","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.rmed.2017.12.009","article-title":"Steroids for sarcoidosis: how much and for how long?","volume":"138","author":"Baughman","year":"2018","journal-title":"Respir Med"},{"key":"2025083110455102000_9.1.e001254.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89518-6"},{"key":"2025083110455102000_9.1.e001254.45","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201010-1679OC"},{"key":"2025083110455102000_9.1.e001254.46","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025083110455102000_9.1.e001254.47","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1513\/AnnalsATS.201707-563OT","article-title":"Executive summary of the NHLBI workshop report: Leveraging current scientific advancements to understand sarcoidosis variability and improve outcomes","volume":"14","author":"Maier","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110455102000_9.1.e001254.48","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.701419","article-title":"A paradigm for Post-Covid-19 fatigue syndrome analogous to ME\/CFS","volume":"12","author":"Mackay","year":"2021","journal-title":"Front Neurol"},{"key":"2025083110455102000_9.1.e001254.49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12603"},{"key":"2025083110455102000_9.1.e001254.50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003773"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:46:03Z","timestamp":1756662363000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjresp-2022-001254"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001254","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}